Actimis Pharmaceuticals Inc
AcquiredSan Mateo, US · Delaware corporation · 1 known investors
Biotech developing small-molecule therapies for respiratory, inflammatory and autoimmune diseases, acquired by Boehringer Ingelheim.
Also known as Actimis
Founders & leadership
Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$452K disclosed across 1 round · 2017
▶$452KraisedJun 2017 · 5 investors · PharmaceuticalsRule 506(b)
- Fred MiddletonDirector
- Peter McWilliamsExecutive Officer, Director
- Kevin BaconExecutive Officer, Director
- Masaji MatsuokaDirector
- Offering amount
- $1M
- Amount sold
- $452K
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Actimis Pharmaceuticals Inc is a privately held biotechnology company focused exclusively on small-molecule therapeutics for severe respiratory, inflammatory and autoimmune diseases, including asthma, inflammatory dermatoses, inflammatory bowel disease and rheumatoid arthritis. Its target selection is centered on the biology of the chemokine superfamily, small proteins released from a variety of cell types under both physiological and pathological conditions.
The company's lead compound, AP767, was in Phase I studies as of mid-2008. AP767 targets the CRTH2 molecule and is intended to modify the course of disease rather than provide symptom control alone; the company reported that the compound demonstrated a more effective mode of action across multiple animal models than marketed leukotriene receptor antagonists. A related asthma candidate, AP768, was the subject of a phased acquisition agreement tied to its progression toward Phase III.
Founding story
The company originated as a November 2004 spin-off from Bayer Healthcare AG.
Business model
Actimis discovered and developed proprietary small-molecule drug candidates, with development funding and regulatory responsibility for its lead asthma program assumed by Boehringer Ingelheim under the 2008 agreement, which also provided for milestone payments.
Latest developments
In June 2008, Boehringer Ingelheim announced plans to acquire Actimis in a structured, phase-dependent buyout valued at up to $515 million including milestone payments, contingent on the success of the asthma candidate.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Positioned in respiratory and inflammatory disease drug development; its asthma candidate was described as complementary to Boehringer Ingelheim's existing respiratory development portfolio, which includes marketed products such as Spiriva for COPD.
Technology
Small-molecule therapeutics directed at targets within the chemokine superfamily. Lead candidate AP767 targets the CRTH2 molecule and was in Phase I as of June 2008; a second asthma candidate, AP768, was tied to phased acquisition milestones.
Go-to-market
Patients with severe respiratory, inflammatory and autoimmune conditions including asthma, inflammatory dermatoses, inflammatory bowel disease and rheumatoid arthritis; pharmaceutical partners for development and commercialization.
Geography
United States operations; described in press coverage as San Diego-based, with internal records listing San Mateo, US.
History
Actimis was spun off from Bayer Healthcare AG in November 2004. In June 2008, German drugmaker Boehringer Ingelheim GmbH agreed to a structured buyout under which it would acquire a prespecified number of Actimis shares at each development phase of the company's experimental asthma drug, eventually acquiring 100 percent of outstanding shares. Boehringer Ingelheim took a minority stake at signing and would own all shares once the candidate AP768 entered Phase III, subject to termination conditions if the drug failed during development.
Risks & controversies
The acquisition structure included termination conditions that could be triggered if the asthma drug candidate failed during development, making full ownership and milestone payments contingent on clinical success.
Compiled by commissioned research from 3 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsBoehringer Ingelheim GmbH said it plans to buy Actimis Pharmaceuticals in a structured buyout, acquiring a prespecified number of shares at each development phase of Actimis' experimental asthma drug and 100% of outstanding shares once AP768 enters Phase III. BI took a minority stake at signing, funds development and regulatory work, and additional milestones could bring total value to $515 million.
$515M source ↗
Actimis Pharmaceuticals was spun off from Bayer Healthcare AG in November 2004.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structure▸Research sources · 3
primary sources listed
- Actimis Pharmaceuticals Inc - Company Profile and News - Bloomberg Marketsbloomberg.com · web
3 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Actimis Pharmaceuticals Inc do?
- Biotech developing small-molecule therapies for respiratory, inflammatory and autoimmune diseases, acquired by Boehringer Ingelheim.
- Who are Actimis Pharmaceuticals Inc's investors?
- Actimis Pharmaceuticals Inc's investors include Mitsui Global Investment.
- How much funding has Actimis Pharmaceuticals Inc raised?
- Actimis Pharmaceuticals Inc has disclosed $452K raised across 1 round.
- Where is Actimis Pharmaceuticals Inc headquartered?
- Actimis Pharmaceuticals Inc is headquartered in San Mateo, US.